Guidelines
The two factors that most influence how osteoarthritis (OA) of the knee is managed are the presence of other health conditions and involvement of other joint sites. As such, for the first time, OARSI has developed guidelines for the non-surgical treatment of osteoarthritis of the knee that are stratified to each of four patient groups: patients with knee-only OA and no comorbidities, patients with knee-only OA with comorbidities, patients with multi-joint OA and no comorbidities, and patients with multi-joint OA with comorbidities. Comorbities included diabetes, hypertension, cardiovascu
For the first time, OARSI has developed treatment guidelines tailored to different types of patients with osteoarthritis (OA) of the knee. These guidelines are based on a comprehensive review of the current scientific evidence for each treatment’s safety and effectiveness. Surgical treatments, the costs of treatments, or their coverage by insurance were not taken into consideration here. These guidelines are designed to help you and your physician determine the best course of treatment for your particular set of circumstances
MOUNT LAUREL, N.J., March 4, 2014, —The Osteoarthritis Research Society International (OARSI)
releases new evidence-based guidelines for the non-surgical treatment of osteoarthritis of the knee
that, for the first time, are targeted to differing patient characteristics. These guidelines, which were
published in the March 2014 issue of the journal Osteoarthritis and Cartilage, offer physicians and
patients a more personalized approach for choosing the best course of treatment for osteoarthritis of
the knee.
The two factors that most influence how osteoarthritis (OA) of the knee is managed are the presence of other health conditions and involvement of other joint sites. As such, for the first time, OARSI has developed guidelines for the non-surgical treatment of osteoarthritis of the knee that are stratified to each of four patient groups: patients with knee-only OA and no comorbidities, patients with knee-only OA with comorbidities, patients with multi-joint OA and no comorbidities, and patients with multi-joint OA with comorbidities. Comorbities included diabetes, hypertension, cardiovascu
Kawaguchi: This roundtable discussion is on the Osteoarthritis Research Society International (OARSI) treatment guidelines, of which part 1 has just been published this year and part 2 on consensus recommendations will be published early in 2008. First of all, please could you give a brief outline of the OARSI treatment guidelines, especially in comparison with the former osteoarthritis (OA) guidelines issued by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR)?
The incidence of osteoarthritis (OA) has been increasing on a global scale. Research is under way to elucidate its causes and pathology; however, no fundamental treatment methods have been established. This roundtable discussion involved leading physicians from the USA, the UK, and Japan, who talked frankly about the current status of and outlook for OA treatment from
their respective viewpoints. Their discussion identified similarities and differences between the countries and proved to be a valuable opportunity for building international consensus on OA treatment.
Recent advances in bioscience at the molecular level and research methods have brought with them a dramatic growth in the volume of medical research conducted at various levels in ever-diversifying specializations. Orthopedics is, of course, no exception; attempts to further explore this therapeutic area have resulted in remarkable progress, with state-of-the-art research in orthopedics now embracing molecular and genetic science, bioengineering, and large-scale randomized comparative clinical studies.
This newsletter has been covering the efforts of the Osteoarthritis Research Society International (OARSI) to optimize treatment for patients with osteoarthritis (OA) worldwide. In 2008, OARSI published its expert consensus recommendations for the management of OA of the hip and knee (Part 2)1, based on an appraisal of existing guidelines and a systematic review of evidence for relevant therapies (Part 1)2.
This newsletter, first published in 2007, covers the efforts of the Osteoarthritis Research Society International (OARSI) to improve the treatment of patients with osteoarthritis (OA). Previous newsletters have covered roundtable discussions by experts on current treatments for OA, the introduction of new recommendations for treating OA, and the future of orthopedic research. This year, the Japanese Orthopaedic Association (JOA) developed Japanese knee OA guidelines based on the OARSI treatment guidelines to provide a ‘bible’ for Japanese clinicians.